RedHill Biopharma Ltd. (RDHL) stock

RDHLNasdaqPharmaceutical Preparations

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 27, 2026Score 0/30

$0.38−0.01 (-1.60%)

Close on Nov 13, 2026Market cap $1.91MP/E –Yield –

RedHill Biopharma ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

RedHill Biopharma has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in RedHill Biopharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-25 reverse split on Aug 20, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is RDHL.

Revenue growth-96.4% · median -35.6%

Operating margin-2776.9% · median -2853.6%

Advertisement
300 × 250

See a number that looks wrong?